Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that on 9 June 2026 it repurchased 68,800 H shares on the Hong Kong Stock Exchange, paying a total of HKD 1.82 million. The buy-back was executed at prices ranging between HKD 25.72 and HKD 27.56, translating to a volume-weighted average cost of HKD 26.49 per share. All repurchased shares are being held as treasury stock.

Following the transaction, outstanding shares (excluding treasury stock) fell to 135.04 million, while treasury shares increased to 1.18 million. Total issued share capital remains unchanged at 136.22 million.

The repurchase forms part of a mandate approved on 12 February 2026 authorising the company to buy back up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 1.18 million shares, representing 0.86 % of the shares outstanding on the mandate date.

Under Hong Kong listing rules, Hanx Biopharmaceuticals is restricted from issuing, selling or transferring shares until 9 July 2026, 30 days after the latest buy-back.